A Study of Selpercatinib (LY3527723) in Healthy Participants
Status:
Completed
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine how safe and how well tolerated selpercatinib
is when given as oral doses to healthy participants. The study will also assess how fast
selpercatinib gets into the blood stream and how long it takes the body to remove it. The
study will last up to about 6 weeks, inclusive of screening period.